 | • レポートコード：MRC2302E0072 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、256ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社では、2021年に1,021.86百万ドルであった世界の頭頸部がん治療薬市場規模が、2022年に1,176.67百万ドルに達し、2027年には年平均成長率15.32%で2,404.25百万ドルまで成長すると予測しています。当調査レポートでは、頭頸部がん治療薬の世界市場の現状について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、競争状況などの構成でまとめております。セグメント分析では、薬物クラス別（化学療法、免疫療法、放射線治療、手術、標的療法）、製品別（ブレオマイシン、セツキシマブ、ドセタキセル、アービタックス、その他）、エンドユーザー別（がん研究機関、クリニック、病院）、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）の情報が含まれています。なお、当市場の主要企業には、AbbVie、Amgen Inc.、AstraZeneca Plc.、BeiGene、Biocon、Bristol-Myers Squibb Company、Celgene Corporation、Eli Lilly and Company Limited、F. Hoffmann-La Roche Ltd.、Fortress Biotech, Inc.、Fresenius Medical Care AG & Co. KGaA、Gilead Sciences、GlaxoSmithKline、Incyte Corp、Johnson & Johnsonなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の頭頸部がん治療薬市場規模：薬物クラス別 - 化学療法の市場規模 - 免疫療法の市場規模 - 放射線治療の市場規模 - 手術の市場規模 - 標的療法の市場規模 ・世界の頭頸部がん治療薬市場規模：製品別 - ブレオマイシンの市場規模 - セツキシマブの市場規模 - ドセタキセルの市場規模 - アービタックスの市場規模 - その他製品の市場規模 ・世界の頭頸部がん治療薬市場規模：エンドユーザー別 - がん研究機関における市場規模 - クリニックにおける市場規模 - 病院における市場規模 ・世界の頭頸部がん治療薬市場規模：地域別 - 南北アメリカの頭頸部がん治療薬市場規模 アメリカの頭頸部がん治療薬市場規模 カナダの頭頸部がん治療薬市場規模 ブラジルの頭頸部がん治療薬市場規模 … - アジア太平洋の頭頸部がん治療薬市場規模 日本の頭頸部がん治療薬市場規模 中国の頭頸部がん治療薬市場規模 インドの頭頸部がん治療薬市場規模 韓国の頭頸部がん治療薬市場規模 台湾の頭頸部がん治療薬市場規模 … - ヨーロッパ/中東/アフリカの頭頸部がん治療薬市場規模 イギリスの頭頸部がん治療薬市場規模 ドイツの頭頸部がん治療薬市場規模 フランスの頭頸部がん治療薬市場規模 ロシアの頭頸部がん治療薬市場規模 … - その他地域の頭頸部がん治療薬市場規模 ・競争状況 ・企業情報 |
The Global Head & Neck Cancer Drugs Market size was estimated at USD 1,021.86 million in 2021 and expected to reach USD 1,176.67 million in 2022, and is projected to grow at a CAGR 15.32% to reach USD 2,404.25 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Head & Neck Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the market was studied across Chemotherapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy.
Based on Product, the market was studied across Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate).
Based on End User, the market was studied across Cancer Research Institutes, Clinics, and Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Head & Neck Cancer Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Head & Neck Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Head & Neck Cancer Drugs Market, including AbbVie, Amgen Inc., AstraZeneca Plc., BeiGene, Biocon, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company Limited, F. Hoffmann-La Roche Ltd., Fortress Biotech, Inc., Fresenius Medical Care AG & Co. KGaA, Gilead Sciences, GlaxoSmithKline, Incyte Corp, Johnson & Johnson, Merck & Co., Inc., NEC Corporation, North Carolina Biotechnology Center, Novartis, Pfizer Inc., Roche Holding AG, Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Head & Neck Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Head & Neck Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Head & Neck Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Head & Neck Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Head & Neck Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Head & Neck Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Head & Neck Cancer Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of head and neck cancer all across the globe
5.1.1.2. Growing consumption of smoking and drinking addictions
5.1.2. Restraints
5.1.2.1. High cost of the drugs
5.1.3. Opportunities
5.1.3.1. Potential growth opportunity in the emerging countries
5.1.3.2. Active presence of late-stage pipeline drugs
5.1.4. Challenges
5.1.4.1. Adverse effect associated with the consumption of the drug
5.2. Cumulative Impact of COVID-19
6. Head & Neck Cancer Drugs Market, by Drug Class
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Radiation therapy
6.5. Surgery
6.6. Targeted Therapy
7. Head & Neck Cancer Drugs Market, by Product
7.1. Introduction
7.2. Bleomycin
7.3. Cetuximab
7.4. Docetaxel
7.5. Erbitux (Cetuximab)
7.6. Hydrea (Hydroxyurea)
7.7. Hydroxyurea
7.8. Keytruda (Pembrolizumab)
7.9. Methotrexate
7.10. Nivolumab
7.11. Opdivo (Nivolumab)
7.12. Pembrolizumab
7.13. Taxotere (Docetaxel)
7.14. Trexall (Methotrexate)
8. Head & Neck Cancer Drugs Market, by End User
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Clinics
8.4. Hospitals
9. Americas Head & Neck Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Head & Neck Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Head & Neck Cancer Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Amgen Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AstraZeneca Plc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. BeiGene
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Biocon
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bristol-Myers Squibb Company
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Celgene Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Eli Lilly and Company Limited
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. F. Hoffmann-La Roche Ltd.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Fortress Biotech, Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Fresenius Medical Care AG & Co. KGaA
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Gilead Sciences
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. GlaxoSmithKline
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Incyte Corp
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Johnson & Johnson
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck & Co., Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. NEC Corporation
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. North Carolina Biotechnology Center
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Novartis
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Pfizer Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Roche Holding AG
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Sanofi
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Sun Pharmaceutical Industries Ltd.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Takeda Pharmaceutical Company Limited
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Teva Pharmaceutical Industries Limited
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing